http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019053117-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_523523e4857f980c860a0d49e77ed0ec |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-26 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56911 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569 |
| filingDate | 2018-09-13^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77000fa66a64b192ffbe084abff7fbef |
| publicationDate | 2019-03-21^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2019053117-A1 |
| titleOfInvention | PCT AND PRO-ADM USED AS CONTROL MARKERS IN ANTIBIOTIC TREATMENT |
| abstract | The invention relates to a method of guidance, stratification and / or control in an antibiotic treatment administered to a patient suffering from an infectious disease; and a method of receiving a treatment with one or more antibiotic agents. In particular, the method comprises: isolating a first sample taken from the patient; isolating a second sample taken from the patient after isolation of the first sample, and starting an antibiotic treatment; determining procalcitonin (PCT) levels or fragment (s) thereof in the first and second samples; and determining a level of proadrenomedullin (proADM) or fragment (s) thereof in at least the second sample. The levels of PCT or fragment (s) thereof in the first and second samples and the rate of pro-ADM or fragment (s) thereof in the second sample indicate whether a change in treatment using to one or more antibiotic agents is necessary. In a preferred embodiment of the invention, the method further comprises determining a level of pro-ADM or fragment (s) thereof in the first and second samples. In a preferred embodiment of the invention, changes in pro-ADM and PCT levels between the first and second samples indicate a need to change or maintain the antibiotic treatment. The invention further relates to a kit for implementing the method of the invention. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3682241-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2724186-C1 |
| priorityDate | 2017-09-13^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 1000 of 1433.
| Next Page | Last Page |